LT2549870T - Karbamoilpiridono darinių ir tarpinių junginių gavimo būdas - Google Patents
Karbamoilpiridono darinių ir tarpinių junginių gavimo būdasInfo
- Publication number
- LT2549870T LT2549870T LTEP11760040.3T LT11760040T LT2549870T LT 2549870 T LT2549870 T LT 2549870T LT 11760040 T LT11760040 T LT 11760040T LT 2549870 T LT2549870 T LT 2549870T
- Authority
- LT
- Lithuania
- Prior art keywords
- intermediates
- preparing
- carbamoylpyridone derivatives
- carbamoylpyridone
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31642110P | 2010-03-23 | 2010-03-23 | |
PCT/US2011/029369 WO2011119566A1 (en) | 2010-03-23 | 2011-03-22 | Process for preparing carbamoylpyridone derivatives and intermediates |
Publications (1)
Publication Number | Publication Date |
---|---|
LT2549870T true LT2549870T (lt) | 2017-07-10 |
Family
ID=44673569
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP17165935.2T LT3260457T (lt) | 2010-03-23 | 2011-03-22 | Karbamoilpiridono darinių ir tarpinių junginių gavimo būdas |
LTEP11760040.3T LT2549870T (lt) | 2010-03-23 | 2011-03-22 | Karbamoilpiridono darinių ir tarpinių junginių gavimo būdas |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEP17165935.2T LT3260457T (lt) | 2010-03-23 | 2011-03-22 | Karbamoilpiridono darinių ir tarpinių junginių gavimo būdas |
Country Status (19)
Country | Link |
---|---|
US (9) | US8889877B2 (lt) |
EP (2) | EP2549870B1 (lt) |
JP (1) | JP5490305B2 (lt) |
KR (1) | KR101440278B1 (lt) |
CN (1) | CN102933080B (lt) |
CY (2) | CY1119143T1 (lt) |
DK (2) | DK3260457T3 (lt) |
ES (2) | ES2856020T3 (lt) |
HR (2) | HRP20170961T1 (lt) |
HU (2) | HUE052848T2 (lt) |
LT (2) | LT3260457T (lt) |
ME (1) | ME02703B (lt) |
PL (2) | PL3260457T3 (lt) |
PT (2) | PT2549870T (lt) |
RS (2) | RS61436B1 (lt) |
SG (1) | SG184186A1 (lt) |
SI (2) | SI3260457T1 (lt) |
TW (1) | TWI582097B (lt) |
WO (1) | WO2011119566A1 (lt) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101700267B1 (ko) | 2008-07-25 | 2017-01-26 | 비이브 헬쓰케어 컴퍼니 | 화합물 |
RU2527451C2 (ru) | 2008-12-11 | 2014-08-27 | Вайв Хелткер Компани | Синтез карбамоилпиридоновых ингибиторов интегразы вич и промежуточных соединений |
SG171731A1 (en) | 2008-12-11 | 2011-07-28 | Glaxosmithkline Llc | Processes and intermediates for carbamoylpyridone hiv integrase inhibitors |
TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
TWI582097B (zh) | 2010-03-23 | 2017-05-11 | Viiv醫療保健公司 | 製備胺甲醯吡啶酮衍生物及中間體之方法 |
LT3456721T (lt) * | 2010-08-05 | 2021-07-12 | Shionogi & Co., Ltd | Junginių, pasižyminčių živ integrazės inhibavimo aktyvumu, gavimo būdas |
PL3067358T3 (pl) | 2012-12-21 | 2020-02-28 | Gilead Sciences, Inc. | Policykliczne związki karbamoilopirydonu i ich zastosowanie farmaceutyczne |
US9573965B2 (en) | 2013-02-19 | 2017-02-21 | Aurobindo Pharma Ltd | Process for the preparation of Dolutegravir |
NO2865735T3 (lt) | 2013-07-12 | 2018-07-21 | ||
LT3019503T (lt) | 2013-07-12 | 2017-11-27 | Gilead Sciences, Inc. | Policikliniai karbamoilpiridono junginiai ir jų panaudojimas živ infekcijų gydymui |
WO2015019310A1 (en) * | 2013-08-07 | 2015-02-12 | Mylan Laboratories Ltd | Process for the preparation of dolute-gravir and intermediates thereof |
US9808428B2 (en) | 2014-01-14 | 2017-11-07 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the delivery of therapeutics |
WO2015110897A2 (en) | 2014-01-21 | 2015-07-30 | Laurus Labs Private Limited | Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof |
WO2015177537A1 (en) * | 2014-05-20 | 2015-11-26 | Cipla Limited | Process for preparing polycyclic carbamoyl pyridone derivatives and intermediates thereof |
NO2717902T3 (lt) | 2014-06-20 | 2018-06-23 | ||
TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
TWI677489B (zh) | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
US11311545B2 (en) | 2014-10-09 | 2022-04-26 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the delivery of therapeutics |
TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
CN104557686A (zh) * | 2014-12-29 | 2015-04-29 | 徐俊烨 | 一种吡啶酮类化合物的合成方法 |
EP3045461A1 (en) | 2015-01-16 | 2016-07-20 | LEK Pharmaceuticals d.d. | Processes for preparing dolutegravir and analogues thereof |
CN107531614B (zh) * | 2015-02-06 | 2020-04-10 | 迈兰实验室有限公司 | 德罗格韦的制备方法 |
TR201905009T4 (tr) | 2015-04-02 | 2019-05-21 | Gilead Sciences Inc | Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları. |
WO2017109649A1 (en) | 2015-12-21 | 2017-06-29 | Lupin Limited | Process for the preparation of hiv integrase inhibitors |
WO2017205585A1 (en) * | 2016-05-27 | 2017-11-30 | Viiv Healthcare Company | Combinations and uses treatments thereof |
CN106565747A (zh) * | 2016-11-10 | 2017-04-19 | 顾世海 | 一种制备度鲁特韦的新方法 |
JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
US11040986B2 (en) | 2017-02-16 | 2021-06-22 | Sandoz Ag | Crystalline forms of cabotegravir sodium |
EP3363802B1 (en) | 2017-02-16 | 2019-11-20 | Sandoz AG | Crystalline form of cabotegravir sodium |
WO2019140365A1 (en) | 2018-01-12 | 2019-07-18 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and formulations thereof |
WO2019159199A1 (en) * | 2018-02-16 | 2019-08-22 | Cipla Limited | Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof |
CA3132832A1 (en) | 2018-04-09 | 2019-10-17 | Howard E. Gendelman | Antiviral prodrugs and formulations thereof |
US11634431B2 (en) | 2018-07-12 | 2023-04-25 | Laurus Labs Limited | Process for purification of protected polycyclic carbamoylpyridone derivatives |
CN109438334A (zh) * | 2018-10-29 | 2019-03-08 | 南京杰运医药科技有限公司 | 一种度鲁特韦中间体的合成方法 |
CN109293675A (zh) * | 2018-11-19 | 2019-02-01 | 遵义医学院 | 一种改进的度鲁特韦制备工艺 |
CN110128448A (zh) * | 2019-05-22 | 2019-08-16 | 博诺康源(北京)药业科技有限公司 | 一种度鲁特韦原料及中间体中非对映异构体杂质的合成方法 |
RU2717101C1 (ru) | 2019-06-03 | 2020-03-18 | Андрей Александрович Иващенко | Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения |
US20200398978A1 (en) | 2019-06-20 | 2020-12-24 | Bell Helicopter Textron Inc. | Low-drag rotor blade extension |
US11248005B2 (en) | 2019-07-08 | 2022-02-15 | Lupin Limited | Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor |
CN111620891B (zh) * | 2020-05-27 | 2023-07-14 | 上海启讯医药科技有限公司 | 一种多替拉韦关键中间体溶剂化物多晶型物及其制备方法和用途 |
CN112500336A (zh) * | 2020-12-15 | 2021-03-16 | 内蒙古永太化学有限公司 | 一种度鲁特韦母核中间体的制备方法 |
CN115572257A (zh) * | 2021-06-21 | 2023-01-06 | 江西帝劢药业有限公司 | 一种吡啶酮类化合物的合成方法 |
CN113816972B (zh) * | 2021-11-17 | 2022-03-18 | 奥锐特药业(天津)有限公司 | 一种hiv抑制剂的制备方法及其中间体晶型 |
CN114605437A (zh) * | 2022-04-01 | 2022-06-10 | 遵义医科大学 | 连续一锅法制备三个替拉韦药物的合成工艺 |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4524149A (en) | 1982-03-15 | 1985-06-18 | Sterling Drug Inc. | 5-Alkanoyl-6-alkyl-2(1H)-pyridinones, their preparation and their cardiotonic use |
US4769380A (en) | 1983-04-29 | 1988-09-06 | Merrell Dow Pharmaceuticals Inc. | Cardiotonic 5-benzoyl-1,2-dihydro-2-oxo-3-pyridinecarboxylates |
US4812474A (en) | 1984-08-16 | 1989-03-14 | G. D. Searle & Co. | Kojic acid ether-ester derivatives |
US4735964A (en) | 1984-08-16 | 1988-04-05 | G. D. Searle & Co. | Kojic acid ether-ester derivatives |
US4603144A (en) | 1984-08-16 | 1986-07-29 | G. D. Searle & Co. | Kojic acid ether-ester derivatives |
GB2280435A (en) | 1993-07-29 | 1995-02-01 | Merck & Co Inc | Anti-viral agent |
DE59611243D1 (de) | 1995-09-29 | 2005-08-11 | Novartis Ag | Hydroxypyridinone |
GB9711093D0 (en) | 1997-05-29 | 1997-07-23 | British Tech Group | Novel orally active iron (III) chelators |
US6452008B2 (en) * | 1998-02-25 | 2002-09-17 | Sumitomo Pharmaceuticals Company, Limited | Pyridone derivatives and process for preparing the same |
US7256286B2 (en) | 1999-11-30 | 2007-08-14 | The Board Of Trustees Of The Leland Stanford Junior University | Bryostatin analogues, synthetic methods and uses |
JP2005505525A (ja) * | 2001-08-02 | 2005-02-24 | ニューロクライン バイオサイエンシーズ, インコーポレイテッド | 性腺刺激ホルモン放出ホルモンレセプターアンタゴニストおよびそれに関連する方法 |
US6426418B1 (en) | 2001-11-02 | 2002-07-30 | Apotex, Inc. | Processes for the manufacturing of 3-hydroxy-N,1,6-trialkyl-4-oxo-1,4-dihydropyridine-2-carboxamide |
CA2379370A1 (en) | 2002-03-28 | 2003-09-28 | Apotex Inc. | Carboxylic acid derivatives of 3-hydroxy-4-oxo-1,4-dihydropyridine as iron chelators |
EP1549315A4 (en) | 2002-09-11 | 2007-05-23 | Merck & Co Inc | DIHYDROXYPYRIDOPYRAZINE-1,6-DION COMPOUNDS AS HIV INTEGRASE INHIBITORS |
AU2003301439A1 (en) | 2002-10-16 | 2004-05-04 | Gilead Sciences, Inc. | Pre-organized tricyclic integrase inhibitor compounds |
TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
DE10349500A1 (de) | 2003-10-23 | 2005-06-02 | Bayer Cropscience Ag | Verfahren zum Herstellen von 2-Dihalogenacyl-3-amino-acrylsäureestern und 3-Dihalogenmethyl-pyrazol-4-carbonsäureestern |
US7645292B2 (en) | 2003-10-27 | 2010-01-12 | Boston Scientific Scimed, Inc. | Vaso-occlusive devices with in-situ stiffening elements |
EP1725554A1 (en) | 2004-03-09 | 2006-11-29 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Hiv integrase inhibitors |
AU2005227258A1 (en) | 2004-03-09 | 2005-10-06 | Merck & Co., Inc. | HIV integrase inhibitors |
JP2007532665A (ja) | 2004-04-14 | 2007-11-15 | ギリアード サイエンシーズ, インコーポレイテッド | Hivインテグラーゼ阻害剤化合物のホスホネート類似物 |
JP4953297B2 (ja) | 2004-09-15 | 2012-06-13 | 塩野義製薬株式会社 | Hivインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体 |
CA2488034C (en) | 2004-11-19 | 2009-10-06 | Apotex Inc. | Process for the manufacture of 3-hydroxy-n-alkyl-1-cycloalkyl-6-alkyl-4-oxo-1,4-dihydropyridine-2-carboxamide and its related analogues |
WO2006065414A2 (en) | 2004-12-16 | 2006-06-22 | General Cable Technology Corporation | Reduced alien crosstalk electrical cable with filler element |
CA2634499A1 (en) | 2004-12-23 | 2006-06-29 | Virochem Pharma Inc. | Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase |
JP5317257B2 (ja) | 2005-02-21 | 2013-10-16 | 塩野義製薬株式会社 | Hivインテグラーゼ阻害活性を有する2環性カルバモイルピリドン誘導体 |
CN101212903B (zh) * | 2005-04-28 | 2013-07-24 | 史密丝克莱恩比彻姆公司 | 具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物 |
EP3372281B1 (en) * | 2005-04-28 | 2021-07-07 | VIIV Healthcare Company | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity |
AR057023A1 (es) | 2005-05-16 | 2007-11-14 | Gilead Sciences Inc | Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa |
JP2006342115A (ja) | 2005-06-10 | 2006-12-21 | Shionogi & Co Ltd | Hivインテグラーゼ阻害活性を有する多環性化合物 |
KR101170120B1 (ko) * | 2005-07-27 | 2012-07-31 | 삼성전자주식회사 | 비안경식 3차원 디스플레이 장치 |
EP1762250A1 (en) | 2005-09-12 | 2007-03-14 | Fresenius Kabi Deutschland GmbH | Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine |
WO2007049676A1 (ja) | 2005-10-27 | 2007-05-03 | Kao Corporation | 脱酸素剤、脱酸素剤中間体、脱酸素剤複合体及びその製造方法 |
TW200800988A (en) | 2005-10-27 | 2008-01-01 | Shionogi & Amp Co Ltd | Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity |
EP2114898A2 (en) | 2007-02-16 | 2009-11-11 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors |
HUE020489T4 (hu) | 2008-07-25 | 2016-01-28 | Viiv Healthcare Co | Dolutegravir elõvegyületek |
KR101700267B1 (ko) * | 2008-07-25 | 2017-01-26 | 비이브 헬쓰케어 컴퍼니 | 화합물 |
WO2010011819A1 (en) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
RU2527451C2 (ru) | 2008-12-11 | 2014-08-27 | Вайв Хелткер Компани | Синтез карбамоилпиридоновых ингибиторов интегразы вич и промежуточных соединений |
SG171731A1 (en) | 2008-12-11 | 2011-07-28 | Glaxosmithkline Llc | Processes and intermediates for carbamoylpyridone hiv integrase inhibitors |
TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
TWI582097B (zh) | 2010-03-23 | 2017-05-11 | Viiv醫療保健公司 | 製備胺甲醯吡啶酮衍生物及中間體之方法 |
LT3456721T (lt) | 2010-08-05 | 2021-07-12 | Shionogi & Co., Ltd | Junginių, pasižyminčių živ integrazės inhibavimo aktyvumu, gavimo būdas |
-
2011
- 2011-03-21 TW TW100109585A patent/TWI582097B/zh active
- 2011-03-22 US US13/636,237 patent/US8889877B2/en active Active
- 2011-03-22 LT LTEP17165935.2T patent/LT3260457T/lt unknown
- 2011-03-22 JP JP2013501383A patent/JP5490305B2/ja active Active
- 2011-03-22 WO PCT/US2011/029369 patent/WO2011119566A1/en active Application Filing
- 2011-03-22 ME MEP-2017-132A patent/ME02703B/me unknown
- 2011-03-22 RS RS20210153A patent/RS61436B1/sr unknown
- 2011-03-22 PL PL17165935T patent/PL3260457T3/pl unknown
- 2011-03-22 DK DK17165935.2T patent/DK3260457T3/da active
- 2011-03-22 DK DK11760040.3T patent/DK2549870T3/en active
- 2011-03-22 KR KR1020127027667A patent/KR101440278B1/ko active IP Right Grant
- 2011-03-22 PT PT117600403T patent/PT2549870T/pt unknown
- 2011-03-22 SI SI201131955T patent/SI3260457T1/sl unknown
- 2011-03-22 RS RS20170586A patent/RS56072B1/sr unknown
- 2011-03-22 EP EP11760040.3A patent/EP2549870B1/en active Active
- 2011-03-22 PL PL11760040T patent/PL2549870T3/pl unknown
- 2011-03-22 ES ES17165935T patent/ES2856020T3/es active Active
- 2011-03-22 HU HUE17165935A patent/HUE052848T2/hu unknown
- 2011-03-22 HU HUE11760040A patent/HUE033863T2/en unknown
- 2011-03-22 SG SG2012070124A patent/SG184186A1/en unknown
- 2011-03-22 EP EP17165935.2A patent/EP3260457B1/en active Active
- 2011-03-22 LT LTEP11760040.3T patent/LT2549870T/lt unknown
- 2011-03-22 CN CN201180015527.6A patent/CN102933080B/zh active Active
- 2011-03-22 PT PT171659352T patent/PT3260457T/pt unknown
- 2011-03-22 ES ES11760040.3T patent/ES2632346T3/es active Active
- 2011-03-22 SI SI201131218A patent/SI2549870T1/sl unknown
-
2014
- 2014-10-14 US US14/513,265 patent/US9120817B2/en active Active
-
2015
- 2015-07-28 US US14/810,518 patent/US9643981B2/en active Active
-
2017
- 2017-03-31 US US15/475,377 patent/US9938296B2/en active Active
- 2017-06-21 CY CY20171100654T patent/CY1119143T1/el unknown
- 2017-06-26 HR HRP20170961TT patent/HRP20170961T1/hr unknown
-
2018
- 2018-02-28 US US15/907,683 patent/US10233196B2/en active Active
- 2018-02-28 US US15/907,626 patent/US10174051B2/en active Active
- 2018-12-03 US US16/207,243 patent/US10654870B2/en active Active
- 2018-12-03 US US16/207,288 patent/US10654871B2/en active Active
- 2018-12-03 US US16/207,273 patent/US10647728B2/en active Active
-
2021
- 2021-02-10 CY CY20211100112T patent/CY1123958T1/el unknown
- 2021-02-15 HR HRP20210255TT patent/HRP20210255T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20170961T1 (hr) | Postupak dobivanja karbamoilpiridonskih derivata i međuprodukata | |
EP2744336A4 (en) | METHOD AND INTERMEDIATE PRODUCTS FOR THE MANUFACTURE OF MACROLACTAMEN | |
EP2550269A4 (en) | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF LAPATINIB | |
IL222290A0 (en) | Process for preparing aminobenzofuran derivatives | |
IL222191A0 (en) | Process for preparing sulfonamido-benzofuran derivatives | |
IL221441A0 (en) | Process for preparing entecavir and its intermediates | |
AP3222A (en) | Germination-stimulant carbamate derivatives and process for preparation thereof | |
ZA201207386B (en) | Process for preparing benzoxaboroles | |
HK1194733A1 (zh) | 製備 -酰基- -苯基磺酰基脯氨酰胺衍生物的方法及中間體 | |
IL227220A (en) | A process for preparing a history of 3-alkylsulfinylbenzoyl | |
IL222243A (en) | Process for the preparation of diethylene-tetracarboxamide derivatives and by-products obtained in this process | |
HK1214599A1 (zh) | 製備 -甲酰基-頭孢霉毒核衍生物的氧化方法 | |
EP2619174A4 (en) | PROCESS FOR THE PREPARATION OF L-PHENYL-3-DIMETHYLAMINOPROPANE DERIVATIVES | |
IL225915A0 (en) | 5-trifluoromethyl-4-nitro-2-isoxazoline compounds and their preparation process | |
IL223145A0 (en) | Process for preparing dithiine-tetracarboxy-diimides | |
EP2585436A4 (en) | PROCESS FOR THE PREPARATION OF 4-HYDROXYPYRIDINES | |
EP2604591A4 (en) | PROCESS FOR THE PREPARATION OF AMINOADAMANTYL CARBAMATE DERIVATIVES | |
EP2578568A4 (en) | PROCESS FOR THE PREPARATION OF 3-SUBSTITUTED FLUOROPYRROLIDINE DERIVATIVES | |
ZA201108148B (en) | Triazine-aryl-bis-indoles and process for preparation thereof | |
PL391303A1 (pl) | Nowa pochodna pirymidopirymidyny i sposób wytwarzania nowej pochodnej pirymidopirymidyny | |
PL391316A1 (pl) | Nowa pochodna pirymidopirymidyny i sposób wytwarzania nowej pochodnej pirymidopirymidyny |